|
Name |
(R)-5-phosphonatomevalonate(3-)
|
| Molecular Formula | C6H10O7P-3 | |
| IUPAC Name* |
(3R)-3-hydroxy-3-methyl-5-phosphonatooxypentanoate
|
|
| SMILES |
C[C@@](CCOP(=O)([O-])[O-])(CC(=O)[O-])O
|
|
| InChI |
InChI=1S/C6H13O7P/c1-6(9,4-5(7)8)2-3-13-14(10,11)12/h9H,2-4H2,1H3,(H,7,8)(H2,10,11,12)/p-3/t6-/m1/s1
|
|
| InChIKey |
OKZYCXHTTZZYSK-ZCFIWIBFSA-K
|
|
| Synonyms |
(R)-5-phosphonatomevalonate(3-); 73566-35-5; (R)-5-phosphonatomevalonate; (R)-mevalonate 5-phosphate; CHEBI:58146; DTXSID30994347; (R)-5-phosphonatomevalonate trianion; 3-Hydroxy-3-methyl-5-(phosphonatooxy)pentanoate; (3R)-3-hydroxy-3-methyl-5-phosphonatooxypentanoate; (3R)-3-hydroxy-3-methyl-5-(phosphonatooxy)pentanoate; Q27125216
|
|
| CAS | 73566-35-5 | |
| PubChem CID | 25244548 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 225.11 | ALogp: | -1.6 |
| HBD: | 1 | HBA: | 7 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 133.0 | Aromatic Rings: | 0 |
| Heavy Atoms: | 14 | QED Weighted: | 0.501 |
| Caco-2 Permeability: | -5.926 | MDCK Permeability: | 0.00099117 |
| Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.002 |
| Human Intestinal Absorption (HIA): | 0.607 | 20% Bioavailability (F20%): | 0.905 |
| 30% Bioavailability (F30%): | 0.978 |
| Blood-Brain-Barrier Penetration (BBB): | 0.647 | Plasma Protein Binding (PPB): | 9.71% |
| Volume Distribution (VD): | 0.262 | Fu: | 75.54% |
| CYP1A2-inhibitor: | 0.002 | CYP1A2-substrate: | 0.091 |
| CYP2C19-inhibitor: | 0.028 | CYP2C19-substrate: | 0.044 |
| CYP2C9-inhibitor: | 0.007 | CYP2C9-substrate: | 0.918 |
| CYP2D6-inhibitor: | 0.026 | CYP2D6-substrate: | 0.107 |
| CYP3A4-inhibitor: | 0.008 | CYP3A4-substrate: | 0.011 |
| Clearance (CL): | 1.6 | Half-life (T1/2): | 0.761 |
| hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.08 |
| Drug-inuced Liver Injury (DILI): | 0.03 | AMES Toxicity: | 0.019 |
| Rat Oral Acute Toxicity: | 0 | Maximum Recommended Daily Dose: | 0.572 |
| Skin Sensitization: | 0.334 | Carcinogencity: | 0.041 |
| Eye Corrosion: | 0.977 | Eye Irritation: | 0.989 |
| Respiratory Toxicity: | 0.171 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001610 | ![]() |
0.500 | D0QC5D | ![]() |
0.308 | ||
| ENC001759 | ![]() |
0.378 | D01EKQ | ![]() |
0.308 | ||
| ENC002634 | ![]() |
0.296 | D04CJL | ![]() |
0.308 | ||
| ENC002702 | ![]() |
0.274 | D07QPM | ![]() |
0.296 | ||
| ENC001900 | ![]() |
0.220 | D0Q4EW | ![]() |
0.296 | ||
| ENC001187 | ![]() |
0.220 | D0OT0O | ![]() |
0.293 | ||
| ENC000643 | ![]() |
0.217 | D00XUN | ![]() |
0.265 | ||
| ENC000377 | ![]() |
0.205 | D08VYC | ![]() |
0.216 | ||
| ENC001245 | ![]() |
0.203 | D03RCJ | ![]() |
0.213 | ||
| ENC000719 | ![]() |
0.200 | D02CYR | ![]() |
0.211 | ||